Melbourne's Zenyth Therapeutics (ASX:ZTL), formerly Amrad, has in-licensed patents from the Ludwig Institute for Cancer Research for antibodies that target a key part of the inflammatory process. [ + ]

Regulatory approval for Chemeq's (ASX:CMQ) polymeric antimicrobial CHEMEQ has been delayed in some jurisdictions, pushing expected registrations out in some cases to 2007. [ + ]

A leading researcher has raised the ire of CSL (ASX:CSL), saying the Melbourne company is "making the wrong vaccine for bird flu." [ + ]

Stem Cell Sciences (AIM:STEM, SCS) and Californian-based Chemicon are set to launch a new product line of culture media for mouse embryonic stem cells. [ + ]

A company has been established in Adelaide to develop scientific techniques for genetic crop testing in Europe.

An Australian replication study has strengthened evidence that individuals who inherit a common variant of the serotonin transporter gene 5-HTT are more vulnerable to major depression after adverse events in their lives. [ + ]

CathRx (ASX:CXD) has taken the first step in the CE Mark approval process for its cardiac diagnostic catheters. [ + ]

Melbourne's Clinuvel Pharmaceuticals (ASX:CUV), formerly Epitan, has begun a trial in Adelaide of its lead drug CUV1647 in a controlled-release pellet form. [ + ]

Milestone payments from partner Nobilon led to Melbourne's BioDiem (ASX:BDM) posting strong results for the half year ending December 31, 2005 with revenue up 88 per cent to $2.9 million and a loss of only $96,000 compared with the previous corresponding half. [ + ]

Pioneering CSIRO plant molecular geneticist Dr Jim Peacock, has been appointed Australia's chief scientist, in the wake of the resignation of Dr Robin Batterham after six years in the job. [ + ]

The Australian life sciences industry has grown significantly in the past five years and shows signs of a positive future, according to the 15th edition of PricewaterhouseCoopers' quarterly BioForum report. [ + ]

Denmark's Bavarian Nordic is actively seeking to be part of the consolidation process now underway in the international vaccine industry, and would not turn down a takeover offer if the price were right, company chairman Asgar Aamund said on Tuesday. [ + ]

Peplin (ASX:PEP) has reported preliminary results of its US-based phase IIa dose escalation clinical trial to establish the maximum tolerated dose of PEP005 in actinic keratosis (AK), also known as solar keratosis, a skin condition which can develop into skin cancer. [ + ]

Singapore-based Rockeby Biomed (ASX:RBY) has signed an exclusive deal to supply its avian flu kits to the Turkish Poultry Industry, an organisation which represents 90 per cent of the poultry industry in Turkey. [ + ]

A team of 12 students from the Bio21 and Howard Florey Institutes scooped the pool at an awards ceremony held last week in Melbourne for the 2005 Young Achievers Australia Biotechnology Entrepreneur program. [ + ]